Prior Authorization and Reauthorization Criteria for Nityr (nitisinone)
Prior authorization and reauthorization criteria for Nityr (nitisinone) for treatment of hereditary tyrosinemia type 1 (HT-1) for UnitedHealthcare members; affects prescribers and pharmacy benefit managers processing requests.
Added exclusion footnote stating Nityr is typically excluded from coverage and tried/failed criteria may be in place.
Reauthorization approval duration set to 12 months (from prior review).
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.